Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery

Epicyt Pharma announced positive topline results from its Phase 1/2a first-in-human study of BAFA, a therapy targeting impaired intestinal calcium uptake. The announcement represents a favorable early clinical-development milestone, although the provided article excerpt does not disclose efficacy, safety, or statistical data.